The global automated and closed cell therapy market size is accounted at USD 1.86 billion in 2025 and is forecasted to hit around USD 11.20 billion by 2034, representing a CAGR of 22.19% from 2025 to 2034. The North America market size was estimated at USD 710 million in 2024 and is expanding at a CAGR of 22.22% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Automated and Closed Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Automated and Closed Cell Therapy Market, by Workflow
8.1.1 Separation
8.1.1.1. Market Revenue and Forecast
8.1.2. Expansion
8.1.2.1. Market Revenue and Forecast
8.1.3. Apheresis
8.1.3.1. Market Revenue and Forecast
8.1.4. Fill – Finish
8.1.4.1. Market Revenue and Forecast
8.1.5. Cryopreservation
8.1.5.1. Market Revenue and Forecast
8.1.6. Others
8.1.6.1. Market Revenue and Forecast
9.1. Automated and Closed Cell Therapy Market, by Type
9.1.1. Stem Cell Therapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Non- Stem Cell Therapy
9.1.2.1. Market Revenue and Forecast
10.1. Automated and Closed Cell Therapy Market, by Scale
10.1.1. Pre-commercial/R&D Scale
10.1.1.1. Market Revenue and Forecast
10.1.2. Commercial scale
10.1.2.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Workflow
11.1.2. Market Revenue and Forecast, by Type
11.1.3. Market Revenue and Forecast, by Scale
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Workflow
11.1.4.2. Market Revenue and Forecast, by Type
11.1.4.3. Market Revenue and Forecast, by Scale
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Workflow
11.1.5.2. Market Revenue and Forecast, by Type
11.1.5.3. Market Revenue and Forecast, by Scale
11.2. Europe
11.2.1. Market Revenue and Forecast, by Workflow
11.2.2. Market Revenue and Forecast, by Type
11.2.3. Market Revenue and Forecast, by Scale
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Workflow
11.2.4.2. Market Revenue and Forecast, by Type
11.2.4.3. Market Revenue and Forecast, by Scale
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Workflow
11.2.5.2. Market Revenue and Forecast, by Type
11.2.5.3. Market Revenue and Forecast, by Scale
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Workflow
11.2.6.2. Market Revenue and Forecast, by Type
11.2.6.3. Market Revenue and Forecast, by Scale
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Workflow
11.2.7.2. Market Revenue and Forecast, by Type
11.2.7.3. Market Revenue and Forecast, by Scale
11.3. APAC
11.3.1. Market Revenue and Forecast, by Workflow
11.3.2. Market Revenue and Forecast, by Type
11.3.3. Market Revenue and Forecast, by Scale
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Workflow
11.3.4.2. Market Revenue and Forecast, by Type
11.3.4.3. Market Revenue and Forecast, by Scale
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Workflow
11.3.5.2. Market Revenue and Forecast, by Type
11.3.5.3. Market Revenue and Forecast, by Scale
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Workflow
11.3.6.2. Market Revenue and Forecast, by Type
11.3.6.3. Market Revenue and Forecast, by Scale
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Workflow
11.3.7.2. Market Revenue and Forecast, by Type
11.3.7.3. Market Revenue and Forecast, by Scale
11.4. MEA
11.4.1. Market Revenue and Forecast, by Workflow
11.4.2. Market Revenue and Forecast, by Type
11.4.3. Market Revenue and Forecast, by Scale
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Workflow
11.4.4.2. Market Revenue and Forecast, by Type
11.4.4.3. Market Revenue and Forecast, by Scale
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Workflow
11.4.5.2. Market Revenue and Forecast, by Type
11.4.5.3. Market Revenue and Forecast, by Scale
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Workflow
11.4.6.2. Market Revenue and Forecast, by Type
11.4.6.3. Market Revenue and Forecast, by Scale
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Workflow
11.4.7.2. Market Revenue and Forecast, by Type
11.4.7.3. Market Revenue and Forecast, by Scale
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Workflow
11.5.2. Market Revenue and Forecast, by Type
11.5.3. Market Revenue and Forecast, by Scale
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Workflow
11.5.4.2. Market Revenue and Forecast, by Type
11.5.4.3. Market Revenue and Forecast, by Scale
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Workflow
11.5.5.2. Market Revenue and Forecast, by Type
11.5.5.3. Market Revenue and Forecast, by Scale
12.1. Thermo Fisher Scientific Inc.
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Miltenyi Biotec GmbH
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Sartorius AG
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Lonza Group AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Terumo BCT, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Fresenius SE & Co. KGaA
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. GE Healthcare
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Pall Corporation
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Asahi Kasei Corporation
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Merck KGaA
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample